Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ$25.11
Market Cap
$3.15B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
456 of 924
Rank in Industry
266 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
APLS Insider Trading Activity
APLS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $14,853,821 | 53 | 100 |
Related Transactions
| Eisele Jeffrey | Chief Development Officer | 0 | $0 | 4 | $57,149 | $-57,149 |
| Chopas James George | VP/Chief Accounting Officer | 0 | $0 | 5 | $105,912 | $-105,912 |
| Lewis Karen | Chief People Officer | 0 | $0 | 4 | $147,094 | $-147,094 |
| Baumal Caroline | Chief Medical Officer | 0 | $0 | 2 | $150,727 | $-150,727 |
| Townsend Adam J. | Chief Commercial Officer | 0 | $0 | 4 | $264,626 | $-264,626 |
| Nicholson Nur | Chief Technical Officer | 0 | $0 | 4 | $284,281 | $-284,281 |
| Sullivan Timothy Eugene | Chief Financial Officer | 0 | $0 | 5 | $458,825 | $-458,825 |
| Watson David O. | General Counsel | 0 | $0 | 6 | $641,031 | $-641,031 |
| DeLong Mark Jeffrey | Chief Business & Strat Officer | 0 | $0 | 6 | $710,552 | $-710,552 |
| Francois Cedric | Chief Executive Officer | 0 | $0 | 4 | $854,932 | $-854,932 |
| Dunlop A. Sinclair | director | 0 | $0 | 3 | $3.86M | $-3.86M |
| Deschatelets Pascal | Chief Scientific Officer | 0 | $0 | 6 | $7.32M | $-7.32M |
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment …
Insider Activity of Apellis Pharmaceuticals, Inc.
Over the last 12 months, insiders at Apellis Pharmaceuticals, Inc. have bought $0 and sold $14.85M worth of Apellis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Apellis Pharmaceuticals, Inc. have bought $10.16M and sold $32.96M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500,000 shares for transaction amount of $20M was made by Morningside Venture Investments Ltd (10 percent owner) on 2021‑11‑18.
List of Insider Buy and Sell Transactions, Apellis Pharmaceuticals, Inc.
| 2025-03-05 | Sale | Watson David O. | General Counsel | 5,569 0.0043% | $25.10 | $139,789 | -3.38% | |
| 2025-02-11 | Sale | DeLong Mark Jeffrey | Chief Business & Strat Officer | 363 0.0003% | $28.54 | $10,360 | -9.11% | |
| 2025-01-29 | Sale | Deschatelets Pascal | Chief Scientific Officer | 826 0.0007% | $29.52 | $24,386 | -6.91% | |
| 2025-01-29 | Sale | Francois Cedric | Chief Executive Officer | 2,824 0.0023% | $29.52 | $83,375 | -6.91% | |
| 2025-01-29 | Sale | Watson David O. | General Counsel | 695 0.0006% | $29.52 | $20,519 | -6.91% | |
| 2025-01-29 | Sale | Sullivan Timothy Eugene | Chief Financial Officer | 546 0.0004% | $29.52 | $16,120 | -6.91% | |
| 2025-01-29 | Sale | DeLong Mark Jeffrey | Chief Business & Strat Officer | 365 0.0003% | $29.52 | $10,776 | -6.91% | |
| 2025-01-29 | Sale | Townsend Adam J. | Chief Commercial Officer | 695 0.0006% | $29.52 | $20,519 | -6.91% | |
| 2025-01-29 | Sale | Nicholson Nur | Chief Technical Officer | 825 0.0007% | $29.52 | $24,357 | -6.91% | |
| 2025-01-29 | Sale | Lewis Karen | Chief People Officer | 364 0.0003% | $29.52 | $10,747 | -6.91% | |
| 2025-01-29 | Sale | Eisele Jeffrey | Chief Development Officer | 278 0.0002% | $29.52 | $8,208 | -6.91% | |
| 2025-01-22 | Sale | Deschatelets Pascal | Chief Scientific Officer | 3,948 0.0032% | $30.43 | $120,120 | -7.96% | |
| 2025-01-22 | Sale | Francois Cedric | Chief Executive Officer | 13,551 0.0109% | $30.43 | $412,296 | -7.96% | |
| 2025-01-22 | Sale | Watson David O. | General Counsel | 3,323 0.0027% | $30.43 | $101,104 | -7.96% | |
| 2025-01-22 | Sale | Sullivan Timothy Eugene | Chief Financial Officer | 3,088 0.0025% | $30.43 | $93,954 | -7.96% | |
| 2025-01-22 | Sale | Townsend Adam J. | Chief Commercial Officer | 3,323 0.0027% | $30.43 | $101,104 | -7.96% | |
| 2025-01-22 | Sale | DeLong Mark Jeffrey | Chief Business & Strat Officer | 1,396 0.0011% | $30.43 | $42,474 | -7.96% | |
| 2025-01-22 | Sale | Nicholson Nur | Chief Technical Officer | 3,948 0.0032% | $30.43 | $120,120 | -7.96% | |
| 2025-01-22 | Sale | Lewis Karen | Chief People Officer | 1,751 0.0014% | $30.43 | $53,275 | -7.96% | |
| 2025-01-22 | Sale | Eisele Jeffrey | Chief Development Officer | 1,291 0.001% | $30.43 | $39,279 | -7.96% |
Total: 359
*Gray background shows transactions not older than one year
Insider Historical Profitability
10.88%
| Sullivan Timothy Eugene | Chief Financial Officer | 128665 0.1025% | $3.23M | 1 | 14 | +1.94% |
| Morningside Venture Investments Ltd | 10 percent owner | 12806342 10.203% | $321.57M | 9 | 0 | +6.91% |
| venBio Global Strategic Fund II L.P. | 10 percent owner | 3579305 2.8517% | $89.88M | 1 | 0 | +31.35% |
| Hillhouse Capital Management, Ltd. | 10 percent owner | 3527152 2.8101% | $88.57M | 1 | 0 | +31.35% |
| Cormorant Asset Management, LLC | 10 percent owner | 3473925 2.7677% | $87.23M | 1 | 0 | +31.35% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$193,151,375 | 134 | 8.18% | $2.8B | |
$11,588,217 | 69 | 42.07% | $2.65B | |
$140,165,669 | 33 | 85.24% | $3.4B | |
$1,275,975,557 | 32 | 19.44% | $2.87B | |
$5,066,938 | 27 | 26.38% | $2.72B |
APLS Institutional Investors: Active Positions
| Increased Positions | 161 | +51.94% | 32M | +26.74% |
| Decreased Positions | 139 | -44.84% | 22M | -18.66% |
| New Positions | 60 | New | 9M | New |
| Sold Out Positions | 67 | Sold Out | 5M | Sold Out |
| Total Postitions | 332 | +7.1% | 129M | +8.08% |
APLS Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Avoro Capital Advisors Llc | $301,400.00 | 9.7% | 12.22M | +1M | +10% | 2024-12-31 |
| Ecor1 Capital, Llc | $293,228.00 | 9.44% | 11.89M | 0 | 0% | 2024-12-31 |
| Wellington Management Group Llp | $291,009.00 | 9.37% | 11.8M | -4M | -24.19% | 2024-12-31 |
| Vanguard Group Inc | $247,735.00 | 7.97% | 10.05M | +230,450 | +2.35% | 2024-12-31 |
| Morgan Stanley | $237,407.00 | 7.64% | 9.63M | +6M | +184.01% | 2024-12-31 |
| Blackrock, Inc. | $159,747.00 | 5.14% | 6.48M | +285,621 | +4.61% | 2024-12-31 |
| State Street Corp | $111,590.00 | 3.59% | 4.53M | +484,294 | +11.98% | 2024-12-31 |
| Deep Track Capital, Lp | $105,420.00 | 3.39% | 4.27M | -125,733 | -2.86% | 2024-12-31 |
| Octagon Capital Advisors Lp | $74,152.00 | 2.39% | 3.01M | 0 | 0% | 2024-12-31 |
| Siren, L.L.C. | $69,449.00 | 2.24% | 2.82M | +649,034 | +29.95% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.